Literature DB >> 8162073

Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types.

A B Bianchi1, T Hara, V Ramesh, J Gao, A J Klein-Szanto, F Morin, A G Menon, J A Trofatter, J F Gusella, B R Seizinger.   

Abstract

The neurofibromatosis 2 gene (NF2) has recently been isolated and predicted to encode a novel protein related to the moesin-ezrin-radixin family of cytoskeleton-associated proteins. Here we describe a novel isoform of the NF2 transcript that shows differential tissue expression and encodes a modified C terminus of the predicted protein. Mutations affecting both isoforms of the NF2 transcript were detected in multiple tumour types including melanoma and breast carcinoma. These findings provide evidence that alterations in the NF2 transcript occur not only in the hereditary brain neoplasms typically associated with NF2, but also as somatic mutations in their sporadic counterparts and in seemingly unrelated tumour types. The NF2 gene may thus constitute a tumour suppressor gene of more general importance in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162073     DOI: 10.1038/ng0294-185

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  64 in total

Review 1.  Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

Authors:  Wei Li; Jonathan Cooper; Matthias A Karajannis; Filippo G Giancotti
Journal:  EMBO Rep       Date:  2012-03       Impact factor: 8.807

2.  Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

3.  Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; P Bono; B Grammatico; P Grammatico; P Radice; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

4.  Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin.

Authors:  Minja Laulajainen; Taru Muranen; Tuula A Nyman; Olli Carpén; Mikaela Grönholm
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

Review 5.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

6.  The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.

Authors:  Anne-Marie Bashour; J-J Meng; Wallace Ip; Mia MacCollin; Nancy Ratner
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

7.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

8.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Authors:  A B Bianchi; S I Mitsunaga; J Q Cheng; W M Klein; S C Jhanwar; B Seizinger; N Kley; A J Klein-Szanto; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  A 163-bp deletion in the neurofibromatosis 2 (NF2) gene associated with variant phenotypes [corrected].

Authors:  L Kluwe; S M Pulst; J Köppen; V F Mautner
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

10.  Cerebrospinal Fluid Hyaluronan and Neurofibromatosis Type 2.

Authors:  Prasanth S Ariyannur; Narendranath Vikkath; Ashok B Pillai
Journal:  Cancer Microenviron       Date:  2018-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.